Alle trials

• MIND-DC (gesloten voor inclusie)
• Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 (gesloten voor inclusie)
• 2125-MEL-301 (Illuminate 301) (gesloten voor inclusie)
• A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)
• A phase 3, randomized, open-label study of NKTR-214
• ADMEC-O (gesloten voor inclusie)
• Adoptive Therapy With TCR Gene-engineered T Cells to Treat Patients With MAGE-C2-positive Melanoma and Head and Neck Cancer (MC2TCR)
• An open label Phase I PET imaging study to investigate the biodistribution and tumor uptake of [89Zr]Zr-BI 765063 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are also treated with ezabenlimab (open voor inclusie)
• ASSUSTENT
• BNI
• Checkmate 914
• Chopin
• CLGK974X2101
• Cowboy studie
• DONIMI
• E7080-G000-218
• Effect of sunitinib on platelet function
• EORTC 1208 (Minitub)
• EORTC 1612
• GCT1021-02
• IMmotion010
• INTRIM
• L19-IL2 with stereotactic ablative body radiotherapy
• M14TIL
• Masterkey 115
• MK-6482-011
• MK-6482-013
• NASAM
• NESCIO-trial
• NIVEC
• Opacin Neo extensiecohort (PRADO cohort) (gesloten)
• OpACIN-neo (gesloten voor inclusie)
• Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumor
• REPOSIT (gesloten voor inclusie)
• SAFE STOP Trial
• SUNIFORECAST
• TIL and anti-PD1 in melanoma
• TRILOGY